152 related articles for article (PubMed ID: 34924268)
61. Actinomyces and MRONJ: A retrospective study and a literature review.
Cerrato A; Zanette G; Boccuto M; Angelini A; Valente M; Bacci C
J Stomatol Oral Maxillofac Surg; 2021 Nov; 122(5):499-504. PubMed ID: 32827811
[TBL] [Abstract][Full Text] [Related]
62. Oral-Health-Related Quality of Life After Surgical Treatment of Osteonecrosis of the Jaws.
Oteri G; De Ponte FS; Runci M; Peditto M; Marcianò A; Cicciù M
J Craniofac Surg; 2018 Mar; 29(2):403-408. PubMed ID: 29135723
[TBL] [Abstract][Full Text] [Related]
63. Further development of the MRONJ minipig large animal model.
Otto S; Pautke C; Martin Jurado O; Nehrbass D; Stoddart MJ; Ehrenfeld M; Zeiter S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1503-1514. PubMed ID: 28803745
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Terms of Staging and Treatment Strategies by Dental Students at Different Educational Levels.
Heimes D; Mark NA; Kuchen R; Pabst A; Becker P; Kyyak S; Thiem DGE; Schulze R; Kämmerer PW
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837455
[No Abstract] [Full Text] [Related]
65. Measurement Properties of the Persian Translated Version of Graves Orbitopathy Quality of Life Questionnaire: A Validation Study.
Kashkouli MB; Karimi N; Aghamirsalim M; Abtahi MB; Nojomi M; Shahrad-Bejestani H; Salehi M
Ophthalmic Epidemiol; 2017 Feb; 24(1):3-10. PubMed ID: 28001456
[TBL] [Abstract][Full Text] [Related]
66. Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study.
Otto S; Schnödt EM; Haidari S; Brunner TF; Aljohani S; Mosleh M; Ristow O; Troeltzsch M; Pautke C; Ehrenfeld M; Fliefel R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):519-526. PubMed ID: 33309263
[TBL] [Abstract][Full Text] [Related]
67. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
68. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
[TBL] [Abstract][Full Text] [Related]
69. Factors Influencing Severity of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study.
Feng Z; An J; Zhang Y
J Oral Maxillofac Surg; 2021 Aug; 79(8):1683-1688. PubMed ID: 33529608
[TBL] [Abstract][Full Text] [Related]
70. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
71. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw.
He L; Sun X; Liu Z; Qiu Y; Niu Y
Int J Oral Sci; 2020 Oct; 12(1):30. PubMed ID: 33087699
[TBL] [Abstract][Full Text] [Related]
72. Fluorescence-guided surgical management of medication-related osteonecrosis of the jaws.
Tomo S; da Cruz TM; Figueira JA; Cunha JLS; Miyahara GI; Simonato LE
Photodiagnosis Photodyn Ther; 2020 Dec; 32():102003. PubMed ID: 32916330
[TBL] [Abstract][Full Text] [Related]
73. A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw.
Auzina D; Slaidina A; Sevastjanova M; Erts R; Lejnieks A; Lejniece S
Stomatologija; 2019; 21(1):13-17. PubMed ID: 31619658
[TBL] [Abstract][Full Text] [Related]
74. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
[TBL] [Abstract][Full Text] [Related]
75. Surgical treatment of medication-related osteonecrosis of the upper jaw: Case series.
Aljohani S; Troeltzsch M; Hafner S; Kaeppler G; Mast G; Otto S
Oral Dis; 2019 Mar; 25(2):497-507. PubMed ID: 30325561
[TBL] [Abstract][Full Text] [Related]
76. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
[TBL] [Abstract][Full Text] [Related]
77. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ).
Pichardo SEC; van der Hee JG; Fiocco M; Appelman-Dijkstra NM; van Merkesteyn JPR
Br J Oral Maxillofac Surg; 2020 Sep; 58(7):771-776. PubMed ID: 32631756
[TBL] [Abstract][Full Text] [Related]
78. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review.
Fortunato L; Bennardo F; Buffone C; Giudice A
J Craniomaxillofac Surg; 2020 Mar; 48(3):268-285. PubMed ID: 32063481
[TBL] [Abstract][Full Text] [Related]
79. Laser surgery in management of medication-related osteonecrosis of the jaws: a meta-analysis.
Momesso GAC; Lemos CAA; Santiago-Júnior JF; Faverani LP; Pellizzer EP
Oral Maxillofac Surg; 2020 Jun; 24(2):133-144. PubMed ID: 32056052
[TBL] [Abstract][Full Text] [Related]
80. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
